Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds

NCT01154088 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1170

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL: Mencevax ACWY
BIOLOGICAL: GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]

Sponsor

GlaxoSmithKline